Bayer’s Xarelto beats aspirin in preventing blood clots

Pharma Times ------ According to results of the Phase III EINSTEIN CHOICE study, presented at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington DC and published in the The New England Journal of Medicine, the as yet unapproved 10mg once daily dose of the oral Factor Xa inhibitor cut relative risk of recurrent VTE by 74 percent compared with aspirin 100mg once daily. On the safety side, among the 3,396 patients rates of major bleeding - a key factor when considering treatment with anticoagulation therapies - was found to be comparable between Xarelto (rivaroxaban) and aspirin. To get more in depth information click on the picture below to read the article.